Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C20H21NO4 |
| Molecular Weight | 339.385 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C2CC3N(CCC4=C3C=C5OCOC5=C4)CC2=C1OC
InChI
InChIKey=VZTUIEROBZXUFA-UHFFFAOYSA-N
InChI=1S/C20H21NO4/c1-22-17-4-3-12-7-16-14-9-19-18(24-11-25-19)8-13(14)5-6-21(16)10-15(12)20(17)23-2/h3-4,8-9,16H,5-7,10-11H2,1-2H3
| Molecular Formula | C20H21NO4 |
| Molecular Weight | 339.385 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Canadine (tetrahydroberberine,THB) is an isoquinoline alkaloid (5,8,13,13a-tetrahydro-9,10-dimethoxy-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine) from Corydalis tuber, it has micromolar affinity for dopamine D(2) (pK(i) = 6.08) and 5-HT(1A) (pK(i) = 5.38) receptors but moderate to no affinity for other relevant serotonin receptors (i.e., 5-HT(1B), 5-HT(1D), 5-HT(3), and 5-HT(4). Canadine enhances gastrointestinal motor function. THB, with D(2) receptor antagonist and 5-HT(1A) receptor agonist properties, has significant potential as a therapeutic for treatment of functional dyspepsia. THB is a potent inhibitor of platelet aggregation in vitro and in vivo and is a promising antithrombotic drug.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL217 |
119.0 nM [Ki] | ||
Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21659472 |
5.38 null [pKi] | ||
Target ID: GO:0070527 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8010106 |
0.86 mM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Preventing | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Structural optimization of berberine as a synergist to restore antifungal activity of fluconazole against drug-resistant Candida albicans. | 2014-01 |
|
| Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing. | 2014-01 |
|
| Tetrahydroberberine blocks ATP-sensitive potassium channels in dopamine neurons acutely-dissociated from rat substantia nigra pars compacta. | 2010-12 |
|
| Simultaneous determination of active xanthone glycosides, timosaponins and alkaloids in rat plasma after oral administration of Zi-Shen Pill extract for the pharmacokinetic study by liquid chromatography-tandem mass spectrometry. | 2010-07-01 |
|
| Revisiting the myths of protein interior: studying proteins with mass-fractal hydrophobicity-fractal and polarizability-fractal dimensions. | 2009-10-16 |
|
| Inhibitory Effects of Coptidis rhizoma and Berberine on Cocaine-induced Sensitization. | 2009-03 |
|
| The neuropharmacology of (-)-stepholidine and its potential applications. | 2007-12 |
|
| Chiral high-performance liquid chromatographic separation of the enantiomers of tetrahydropalmatine and tetrahydroberberine, isolated from Corydalis yanhusuo. | 2006-02 |
|
| [Chemical constituents from Corydalis humosa]. | 2005-07 |
|
| Chlorobenzylidine-calf thymus DNA interaction II: circular dichroism and nuclear magnetic resonance studies. | 2004-11 |
|
| In vitro anti-proliferation/cytotoxic activity of sixty natural products on the human SH-SY5Y neuroblastoma cells with specific reference to dibenzyl trisulphide. | 2004-09 |
|
| [Inhibitory action of CPU86035 on L-type calcium current in single ventricular myocyte of guinea pig]. | 2002-01-10 |
|
| Cardiovascular actions of berberine. | 2001 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21659472
Rats: Oral administration of Canadine not only resulted in the significantly accelerated gastric emptying of normal rats in a bell-shaped relationship, with a maximal efficacy at a dose of 30 ug/kg, but also restored the delayed gastric emptying caused by apomorphine, which might be mediated by an antidopaminergic effect.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12515216
Canadine (tetrahydroberberine,THB) (0.1-10 uM/L) shifted the dose-response curves to the right in a nonparallel fashion and decreased the maximal response (Emax) of both the fenoldopam(FODA, a selective DA1 agonist)-induced and the propyl-butyl-dopamine(PBDA, a selective DA2 agonist)-induced vasorelaxation, showing a non-competitive antagonistic action. The pD'2 values of THB for FODA in the renal, pulmonary and mesenteric arteries were 5.29, 5.37 and 5.46, respectively, while for PBDA in the mesenteric and femoral arteries were 5.53 and 5.48, respectively.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:09:49 GMT 2025
by
admin
on
Mon Mar 31 21:09:49 GMT 2025
|
| Record UNII |
V2SSH085X8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CANADINE
Created by
admin on Mon Mar 31 21:09:49 GMT 2025 , Edited by admin on Mon Mar 31 21:09:49 GMT 2025
|
PRIMARY | |||
|
22998
Created by
admin on Mon Mar 31 21:09:49 GMT 2025 , Edited by admin on Mon Mar 31 21:09:49 GMT 2025
|
PRIMARY | |||
|
28111-09-3
Created by
admin on Mon Mar 31 21:09:49 GMT 2025 , Edited by admin on Mon Mar 31 21:09:49 GMT 2025
|
SUPERSEDED | |||
|
36351
Created by
admin on Mon Mar 31 21:09:49 GMT 2025 , Edited by admin on Mon Mar 31 21:09:49 GMT 2025
|
PRIMARY | |||
|
DTXSID5022724
Created by
admin on Mon Mar 31 21:09:49 GMT 2025 , Edited by admin on Mon Mar 31 21:09:49 GMT 2025
|
PRIMARY | |||
|
C004645
Created by
admin on Mon Mar 31 21:09:49 GMT 2025 , Edited by admin on Mon Mar 31 21:09:49 GMT 2025
|
PRIMARY | |||
|
m3008
Created by
admin on Mon Mar 31 21:09:49 GMT 2025 , Edited by admin on Mon Mar 31 21:09:49 GMT 2025
|
PRIMARY | Merck Index | ||
|
26548-75-4
Created by
admin on Mon Mar 31 21:09:49 GMT 2025 , Edited by admin on Mon Mar 31 21:09:49 GMT 2025
|
SUPERSEDED | |||
|
34458
Created by
admin on Mon Mar 31 21:09:49 GMT 2025 , Edited by admin on Mon Mar 31 21:09:49 GMT 2025
|
PRIMARY | |||
|
94918
Created by
admin on Mon Mar 31 21:09:49 GMT 2025 , Edited by admin on Mon Mar 31 21:09:49 GMT 2025
|
PRIMARY | |||
|
29074-38-2
Created by
admin on Mon Mar 31 21:09:49 GMT 2025 , Edited by admin on Mon Mar 31 21:09:49 GMT 2025
|
SUPERSEDED | |||
|
V2SSH085X8
Created by
admin on Mon Mar 31 21:09:49 GMT 2025 , Edited by admin on Mon Mar 31 21:09:49 GMT 2025
|
PRIMARY | |||
|
522-97-4
Created by
admin on Mon Mar 31 21:09:49 GMT 2025 , Edited by admin on Mon Mar 31 21:09:49 GMT 2025
|
PRIMARY | |||
|
208-338-2
Created by
admin on Mon Mar 31 21:09:49 GMT 2025 , Edited by admin on Mon Mar 31 21:09:49 GMT 2025
|
PRIMARY | |||
|
4979-14-0
Created by
admin on Mon Mar 31 21:09:49 GMT 2025 , Edited by admin on Mon Mar 31 21:09:49 GMT 2025
|
SUPERSEDED |